Ingevec Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Ingevec heeft een totaal eigen vermogen van CLP84.8B en een totale schuld van CLP86.2B, wat de schuld-eigenvermogensverhouding op 101.7% brengt. De totale activa en totale passiva bedragen respectievelijk CLP242.3B en CLP157.5B. De EBIT Ingevec is CLP12.1B waardoor de rentedekking 3.4 is. Het heeft contanten en kortetermijnbeleggingen van CLP16.1B.

Belangrijke informatie

101.7%

Verhouding schuld/eigen vermogen

CL$86.23b

Schuld

Rente dekkingsratio	3.4x
Contant	CL$16.11b
Aandelen	CL$84.80b
Totaal verplichtingen	CL$157.55b
Totaal activa	CL$242.35b

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Jun 14

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Jan 11

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Apr 12

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Jan 11

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Ingevec S.A.'s (SNSE:INGEVEC) Performance Completely

Jan 26

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Jun 14

A Look At The Intrinsic Value Of Ingevec S.A. (SNSE:INGEVEC)

Feb 16

Slowing Rates Of Return At Ingevec (SNSE:INGEVEC) Leave Little Room For Excitement

Sep 02

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Jan 11

Key Things To Consider Before Buying Ingevec S.A. (SNSE:INGEVEC) For Its Dividend

Jan 26

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Jan 11

Did You Participate In Any Of Ingevec's (SNSE:INGEVEC) Incredible 423% Return?

Dec 23

We Wouldn't Rely On Ingevec's (SNSE:INGEVEC) Statutory Earnings As A Guide

Dec 01

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CLP118.1B ) van INGEVEC } dekken niet de korte termijn passiva ( CLP128.5B ).

Langlopende schulden: De kortetermijnactiva INGEVEC ( CLP118.1B ) overtreffen de langetermijnschulden ( CLP29.0B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 82.7% ) INGEVEC wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van INGEVEC is de afgelopen 5 jaar gedaald van 117.6% naar 101.7%.

Schuldendekking: De schuld van INGEVEC wordt goed gedekt door de operationele kasstroom ( 20.6% ).

Rentedekking: De rentebetalingen op de schuld van INGEVEC worden goed gedekt door EBIT ( 3.4 x dekking).

Ingevec Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Recent updates

Third quarter 2024 earnings released: EPS: CL$2.82 (vs CL$2.07 in 3Q 2023)

Upcoming dividend of CL$2.90 per share

First quarter 2024 earnings released: EPS: CL$3.00 (vs CL$2.70 in 1Q 2023)

New major risk - Financial position

Full year 2023 earnings released: EPS: CL$9.70 (vs CL$9.30 in FY 2022)

Even With A 26% Surge, Cautious Investors Are Not Rewarding Ingevec S.A.'s (SNSE:INGEVEC) Performance Completely

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CL$2.07 (vs CL$2.24 in 3Q 2022)

New major risk - Financial position

Second quarter 2023 earnings released: EPS: CL$2.68 (vs CL$2.49 in 2Q 2022)

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Full year 2022 earnings released: EPS: CL$9.30 (vs CL$8.60 in FY 2021)

A Look At The Intrinsic Value Of Ingevec S.A. (SNSE:INGEVEC)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Investor sentiment improved over the past week

Slowing Rates Of Return At Ingevec (SNSE:INGEVEC) Leave Little Room For Excitement

Second quarter 2022 earnings released: EPS: CL$2.49 (vs CL$2.08 in 2Q 2021)

First quarter 2022 earnings released: EPS: CL$2.70 (vs CL$2.20 in 1Q 2021)

Upcoming dividend of CL$4.30 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

The Returns At Ingevec (SNSE:INGEVEC) Aren't Growing

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CL$2.21 (vs CL$0.97 in 3Q 2020)

Second quarter 2021 earnings released: EPS CL$2.08 (vs CL$0.06 in 2Q 2020)

Here's What's Concerning About Ingevec's (SNSE:INGEVEC) Returns On Capital

First quarter 2021 earnings released: EPS CL$2.20 (vs CL$1.72 in 1Q 2020)

Upcoming dividend of CL$1.56 per share

Calculating The Fair Value Of Ingevec S.A. (SNSE:INGEVEC)

Upcoming dividend of CL$1.56 per share

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS CL$5.20 (vs CL$7.80 in FY 2019)

New 90-day high: CL$90.00

Here’s What’s Happening With Returns At Ingevec (SNSE:INGEVEC)

Is Ingevec S.A.'s (SNSE:INGEVEC) ROE Of 9.7% Impressive?

Key Things To Consider Before Buying Ingevec S.A. (SNSE:INGEVEC) For Its Dividend

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Did You Participate In Any Of Ingevec's (SNSE:INGEVEC) Incredible 423% Return?

New 90-day low: CL$79.78

We Wouldn't Rely On Ingevec's (SNSE:INGEVEC) Statutory Earnings As A Guide

Third quarter 2020 earnings released: EPS CL$0.97

New 90-day low: CL$82.25

New 90-day low: CL$85.20

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven